The Irish Times (Free subscription) | 10/24/2009
SHARES IN Elan slumped yesterday after the European Medicinces Agency (EMEA) announced a review of the risks and benefits of its key multiple sclerosis drug Tysabri in the wake of 23 cases of a rare and potentially fatal brain disease since it came to market.
Market Watch (Free subscription) | 10/23/2009
BOSTON (MarketWatch) -- Partners Biogen Idec and Elan Corp. led drug stocks lower early Friday as shares of the companies fell on news that European regulators were reviewing the safety of their multiple sclerosis drug Tysabri. The NYSE Arca Pharmaceutical Index declined 0.6% to 293.92 and the NYSE Arca Biotechnology Index fell 1% to 889.92. Biogen shares were off 5% at $44.80,...
ireland.com (Free subscription) | 10/23/2009
Text Size:Last Updated: Friday, October 23, 2009, 16:17Elan shares drop on Tysabri reviewEuropean regulators said they have begun a review of multiple sclerosis drug Tysabri following reports of 23 cases of a potentially deadly brain infection.Tysabri, which is made by Irish biotechnology company Elan and US firm biogen, was temporarily withdrawn from the market in 2005 after being...
The Street (Free subscription) | 10/23/2009
Biogen and Elan shares fall as European regulators investigate Tysabri brain infection reports.
PharmaGossip (Free subscription) | 09/30/2009
Elan has received a US Securities and Exchange Commission (SEC) subpoena over the pharmaceutical company's disclosure of two cases of an often fatal brain disorder tied to the use of its Tysabri multiple sclerosis drug, which sent the shares plunging by 64pc in a three-day period last year. Elan received the subpoena in connection with the disclosure last year, the company said...
Reuters UK (Free subscription) | 09/29/2009
NEW YORK (Reuters) - Elan Corp Plc said on Tuesday it received a U.S. Securities and Exchange Commission subpoena over its disclosure of two cases of an often fatal brain disorder tied to use of its Tysabri multiple sclerosis drug.
Top Stories: BreakingNews.ie (Free subscription) | 10/30/2009
The total value of equities traded on the ISEQ index of Irish shares fell from €96bn a year ago to €40.8bn at the end of September 2009.
